Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

Lupus

Volumn 16, Issue 6, 2007, Pages 401-409

  James, J A ^a,b   Kim Howard, X R ^a   Bruner, B F ^a,b   Jonsson, M K ^c   McClain, M T ^a   Arbuckle, M R ^a   Walker, C ^d   Dennis, G J ^d,e   Merrill, J T ^a   Harley, J B ^a,b,f  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Hydroxychloroquine; SLE; Systemic lupus erythematosus; Therapy

Indexed keywords

AUTOANTIBODY; HYDROXYCHLOROQUINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PLEURISY; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODY SPECIFICITY; AUTOANTIBODIES; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MILITARY PERSONNEL; PREDNISONE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 34547208786     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307078579     Document Type: Article

References (21)

1. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25(11): 1271-1277.
2. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
3. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349(16): 1526-1533.
4. Wallace DJ. Antimalarials - the 'real' advance in lupus. Lupus 2001; 10(6): 385-387.
5. D'Cruz D. Antimalarial therapy: a panacea for mild lupus? Lupus 2001; 10(3): 148-151.
6. Tsakonas E, Joseph L, Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7(2): 80-85.
7. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991; 324(3): 150-154.
8. Molad Y, Gorshtein A, Wysenbeek AJ et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002; 11(6): 356-361.
9. Fessler BJ, Alrcon GS, McGwin G et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473-1480.
10. Costedoat-Chalumeau N, Ameura Z, Hulot JS et al. Low blood concentrations of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:3284-3290.
11. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain JB, Aguirre C. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577-583.
12. McClain MT, Ramsland PA, Kaufman KM, James JA. Anti-Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J Immunol 2002; 168: 2054-2062.
13. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6.
14. Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S. Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus 1998; 7(2): 95-100.
15. Alarcon GS, Williams GV, Singer JZ et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol 1991; 18(9): 1332-1339.
16. Danieli MG, Fraticelli P, Franceschini F et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol 1999; 17(5): 585-591.
17. Cavazzana I, Franceschini F, Belfiore N et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol 2001; 19(4): 403-409.
18. Clegg DO, Williams HJ, Singer JZ et al. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991; 18(9): 1340-1343.
19. Calvo-Alen J, Alarcon GS, Burgard SL, Burst N, Bartolucci AA, Williams HJ. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol 1996; 23(3): 469-475.
20. Ganczarczyk L, Urowitz MB, Gladman DD. Latent lupus. J Rheumatol 1989; 16(4): 475-478.
21. Allen E, Farewell VT, Isenberg DA, Gordon C. A statistical analysis of the interrelationships between disease activity in different systems in systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45(3): 308-313.